SARS-CoV-2-IN-19 is a potent SARS-CoV-2 inhibitor with an EC50 of 8.8 μM; it exhibits effective activity against the SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting its potential against emerging human coronavirus (HCoV) outbreaks; it has potential for research in infectious diseases.